BY GINA CHON AND ANUPREETA DAS
France's Sanofi-Aventis SA may not be the only large drug maker to set its eyes on struggling biotechnology company Genzyme Corp. After news of Sanofi's interest in the U.S. company became public Friday, investors and bankers are scrambling to find out whether Sanofi's rivals could also be interested in making a play for Genzyme, which makes drugs for rare, inherited disorders.
Britain's GlaxoSmithKline PLC and New Jersey-based Johnson & Johnson are seen as the most logical suitors for Genzyme, bankers and analysts said.
Pero a Sanofi Aventis ya le han dicho que NO...
VerVer tambien
Entradas
No hay comentarios:
Publicar un comentario